Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Drug Induced Movement Disorder, Unspecified
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
D2 dopaminergic receptor blockers, used to treat schizophrenia, can lead to the onset of movement disorders. Drug-induced movement disorders encompass several syndromes.
- Conditions
- Schizophrenia, Drug Induced Movement Disorder, Unspecified, Oxidative Stress
- Trial name
- NCT03790345
- Testing
- Pyridoxine, Cobalamin
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Schizoaffective Disorder
LRFN5 and OLFM4 in Schizoaffective Disorder
Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and…
- Trial name
- NCT07447960
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Elazığ Mental Health and Diseases Hospital
Schizophrenia, Diabetes
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
- Trial name
- NCT00287820
- Testing
- Olanzapine, risperidone
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or…
- Trial name
- NeSSy (NCT01164059)
- Testing
- Olanzapine, Flupentixol, Quetiapine
- Where
- 18 sites in Germany
- Volunteers
- 149 people
- Sponsor
- University of Bremen
Schizophrenia
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic…
- Trial name
- NCT01234454
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Psychotic Disorders
Cognitive Remediation and Supported Education in Psychotic Disorders
This trial aims to assess the added value of cognitive remediation therapy to supported education intervention in young adults with a psychotic disorder.
- Trial name
- REUSSIR (NCT04040829)
- Testing
- Cognitive remediation therapy (CR), Supported education (SE), Treatment as usual (TAU)
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Schizophrenia
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
The study aims to investigate the modulation of regional brain activation in schizophrenic patients by psychopharmacological treatment with either haloperidol, amisulpride or olanzapine.
- Trial name
- NCT00419653
- Testing
- Amisulpride, Olanzapine, Haloperidol
- Volunteers
- 19 people
- Sponsor
- University of Jena
Schizophrenia, Schizoaffecitve Disorder
Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder
The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue…
- Trial name
- NCT07755605
- Testing
- Digital therapeutic (AffectUs), Psychoeducational materials
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Catatonia, Schizophrenia
Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia
Evaluation effectiveness and safety of TMS in subjects with catatonia
- Conditions
- Catatonia, Schizophrenia, Schizo Affective Disorder, Bipolar Affective Disorder
- Trial name
- RECATA (NCT06176456)
- Testing
- rTMS
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Moscow Psychiatric Hospital No. 1 Named after N.A. Alexeev
Schizophrenia, Anosognosia
The Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
This study aims to determine the clinical and functional imaging effects of serial CVS on illness awareness in schizophrenia. Specifically, the investigators aim to: 1.
- Trial name
- NCT05957484
- Testing
- Investigational brainstem neuromodulation device
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Impulsive Behavior
Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally…
- Trial name
- NCT03838484
- Testing
- Nicotine Patch, 7 Mg/24 Hr
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Recruitment, Invitation Letters, Patients With Schizophrenia
Recruitment of Patients Through Invitation Letters
Recruitment of patients with schizophrenia to clinical trials is difficult and in an ongoing project different methods of recruitment have been used in order to recruit.
- Trial name
- NCT03590015
- Testing
- Old invitation letter, New invitation Letter
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Aalborg University Hospital
Schizophrenia
A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia
The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 \& 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor…
- Trial name
- NCT00455715
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases.
- Trial name
- NCT00535574
- Testing
- Bexarotene (Targretin LGD1069), bexarotene
- Where
- 3 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Beersheva Mental Health Center
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to understand the impact of less…
- Trial name
- NCT03809325
- Testing
- Paliperidone Palmitate 3-Month Formulation (PP3M)
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 225 people
- Sponsor
- Janssen-Cilag International NV
First Episode Psychosis, Psychosis
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness…
- Conditions
- First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective
- Trial name
- NCT04298450
- Testing
- Active SMS Intervention
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia
Mindfulness Psychoeducation for Schizophrenia
This study aims to examine the effects of a mindfulness-based psychoeducation program on mindfulness levels and treatment adherence among individuals diagnosed with schizophrenia.
- Trial name
- NCT07310615
- Testing
- Mindfulness-Based Psychoeducation Program, Routine Care
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ömer USLU
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.